What the buyer wrote
Procurement of Revcovi, an approved enzyme replacement therapy (ERT) indicated for the treatment of adenosine deaminase severe combined immune deficiency.
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Details
- What the buyer calls it
- Revcovi
- How they are buying
- Given to one supplier, no competitionNobody else was asked, and the buyer has to be able to justify that.
- Work starts
- 14 Sep 2025
- Work ends
- 14 Sep 2028
- Where
- in Northern Ireland
Who the buyer named
The buyer published a contact address on this notice.